辛伐他丁对淋巴瘤CA46细胞凋亡的影响及机制

被引：1

作者：

陈连香 ^{[1
]}

肖镇 ^{[1
]}

王威 ^{[2
]}

机构：

[1] 内蒙古医科大学附属医院血液内科

[2] 内蒙古自治区人民医院急诊科

来源：

海南医学院学报 | 2014年 / 20卷 / 02期

关键词：

辛伐他汀; 淋巴瘤; CA46; 细胞凋亡;

D O I：

10.13210/j.cnki.jhmu.2014.02.036

中图分类号：

R733.1 [网状内皮系统肿瘤];

学科分类号：

100214 ;

摘要：

目的:研究内源性胆固醇合成限速酶(HMG-CoA)还原酶抑制剂辛伐他汀对淋巴瘤细胞凋亡的影响及分子机制。方法:辛伐他汀对淋巴瘤CA46细胞株进行干预,MTT法评价二者对癌细胞增殖的影响;流式细胞计量术检测细胞凋亡;免疫印迹法检测凋亡相关蛋白多聚ADP核糖多聚糖蛋白(PARP)、半胱氨酸蛋白酶-3(Caspase-3)、凋亡相关基因Bax、Bcl-2表达情况。结果:辛伐他汀干预可显著抑制CA46细胞MTT活性,辛伐他汀作用还可促进CA46细胞凋亡的启动,且均呈剂量-效应关系;辛伐他汀干预还可引发CA46肿瘤细胞Caspase-3活性水平升高,PARP裂解失活,促凋亡蛋白Caspase-3、Bax高表达,抗凋亡蛋白Bcl-2表达降低,且均呈现时间-效应关系。结论:辛伐他汀对淋巴瘤CA46细胞具有增殖抑制和促凋亡效应,其机制可能与caspase家族介导的蛋白酶级联反应、PARP裂解失活以及Bcl-2家族介导的细胞色素C途径有关。

引用

页码：165 / 168

页数：4

共 8 条

[1]

Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non‐small lung cancer cells[J] . G. Pelaia,L. Gallelli,T. Renda,D. Fratto,D. Falcone,M. Caraglia,M. T. Busceti,R. Terracciano,A. Vatrella,R. Maselli,R. Savino.Cell Prolif. . 2012 (6)

[2]

Involvement of Chk1–Cdc25A-cyclin A/CDk2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells[J] . Yong-Sheng Tu,Xiao-Long Kang,Jia-Guo Zhou,Xiao-Fei Lv,Yong-Bo Tang,Yong-Yuan Guan.European Journal of Pharmacology . 2011 (2)

[3] Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress [J].

Sanchez, Claudia A. ;

Rodriguez, Emma ;

Varela, Elvira ;

Zapata, Estrella ;

Paez, Araceli ;

Masso, Felipe A. ;

Montano, Luis F. ;

Lopez-Marure, Rebeca .

CANCER INVESTIGATION, 2008, 26 (07) :698-707

[4] Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status [J].

Cemeus, Catia ;

Zhao, Tong T. ;

Barrett, Gordon M. ;

Lorimer, Ian A. ;

Dimitroulakos, Jim .

JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) :9-17

[5]

Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK[J] . Meral Koyuturk,Melike Ersoz,Nedret Altiok.Cancer Letters . 2006 (2)

[6] Tumor senescence as a determinant of drug response in vivo [J].

Roninson, IB .

DRUG RESISTANCE UPDATES, 2002, 5 (05) :204-208

[7]

Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors[J] . Xu Luo,Imawati Budihardjo,Hua Zou,Clive Slaughter,Xiaodong Wang.Cell . 1998 (4)

[8] Human ICE/CED-3 protease nomenclature [J].

Alnemri, ES ;

Livingston, DJ ;

Nicholson, DW ;

Salvesen, G ;

Thornberry, NA ;

Wong, WW ;

Yuan, JY .

CELL, 1996, 87 (02) :171-171

← 1 →